AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21752292 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized mixed oil preparation (aloe, coconut, orange, peppermint, vitamin E)
Number of subjects: 12
Study 21752292 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized mixed oil preparation
Number of subjects: 12
Study 21752292 — intervention group
Group type: EXPERIMENTAL
Intervention: Orange oil
Number of subjects: 12
Study 19845550 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 146
Study 19845550 — intervention group
Group type: COMPARATOR
Intervention: Propofol with alfentanil
Number of subjects: 146
Study 16709210 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week scan policy
Number of subjects: 39572
Study 16709210 — intervention group
Group type: COMPARATOR
Intervention: 18-week scan policy
Number of subjects: 39572
Study 14706058 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedtime diazoxide, 100 mg
Number of subjects: 27
Study 14706058 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 11034946 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac troponin T >0.10 ng/mL
Number of subjects: 102
Study 11034946 — intervention group
Group type: EXPERIMENTAL
Intervention: Total homocysteine level greater than median
Number of subjects: 102
Study 11034946 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline glucose (1 mmol/L increase)
Number of subjects: 102
Study 11034946 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline triglycerides (1 mmol/L increase)
Number of subjects: 102
Study 8810610 — intervention group
Group type: EXPERIMENTAL
Intervention: TGF-beta release in BAL cell culture (n=12; 1,422 +/- 215 pg/ml; p < 0.004)
Number of subjects: 46
Study 8810610 — intervention group
Group type: EXPERIMENTAL
Intervention: TGF-beta release in BAL cell culture (n=21; 677 +/- 159 pg/ml)
Number of subjects: 46
Study 8810610 — intervention group
Group type: EXPERIMENTAL
Intervention: TGF-beta release in BAL cell culture (n=6; 762 +/- 419 pg/ml)
Number of subjects: 46
Study 8810610 — intervention group
Group type: EXPERIMENTAL
Intervention: TGF-beta release in BAL cell culture (n=5; 1,560 +/- 353 pg/ml)
Number of subjects: 46
Study 8810610 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-10 release
Number of subjects: 46
Study 8810610 — intervention group
Group type: COMPARATOR
Intervention: TGF-beta release in BAL cell culture (612 +/- 261.2 pg/ml)
Number of subjects: 46
Study 1565532 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin estolate (EST) 40 mg/kg/day divided in 2 doses
Number of subjects: 190
Study 1565532 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin ethylsuccinate (ETH) 60 mg/kg/day divided in 3 doses
Number of subjects: 190
Study 1565532 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin estolate (EST)
Number of subjects: 190
Study 1565532 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin ethylsuccinate (ETH)
Number of subjects: 190
Study 3907818 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (retinyl palmitate)
Number of subjects: 376
Study 3907818 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0 IU)
Number of subjects: 376
Study 31857506 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 1000 mg/d
Number of subjects: 201
Study 31857506 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 201
Study 29035923 — intervention group
Group type: EXPERIMENTAL
Intervention: Desktop USB‐powered humidifier
Number of subjects: 44
Study 29035923 — intervention group
Group type: COMPARATOR
Intervention: No humidifier (control)
Number of subjects: 44
Study 25912176 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month exercise and behavioral weight loss intervention
Number of subjects: 19
Study 25912176 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 19
Study 24456026 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus with reduced-dose tacrolimus (loading dose: 15 mg, initial dose: 5 mg titrated to a trough of 4-11 ng/mL; reduced-dose tacrolimus trough: 3-7 ng/mL)
Number of subjects: 222
Study 24456026 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus with reduced-dose tacrolimus
Number of subjects: 222
Study 24456026 — intervention group
Group type: COMPARATOR
Intervention: Conventional-dose tacrolimus (trough: 7-15 ng/mL)
Number of subjects: 222
Study 24456026 — intervention group
Group type: COMPARATOR
Intervention: Conventional-dose tacrolimus
Number of subjects: 222
Study 21843929 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone + Resistance Training (TR)
Number of subjects: 40
Study 21843929 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo + Resistance Training (PR)
Number of subjects: 40
Study 21843929 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone + No Training (T)
Number of subjects: 40
Study 21843929 — intervention group
Group type: COMPARATOR
Intervention: Placebo + No Training (P)
Number of subjects: 40
Study 19043140 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin (40 mg/day)
Number of subjects: 135
Study 19043140 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (80 mg/day)
Number of subjects: 135
Study 19043140 — intervention group
Group type: COMPARATOR
Intervention: Rosuvastatin and Atorvastatin (comparison)
Number of subjects: 135
Study 19043140 — intervention group
Group type: COMPARATOR
Intervention: Rosuvastatin and Atorvastatin (absolute values)
Number of subjects: 135
Study 17438403 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 20
Study 17438403 — intervention group
Group type: COMPARATOR
Intervention: Control (nothing)
Number of subjects: 20
Study 15346302 — intervention group
Group type: COMPARATOR
Intervention: Healthy test subjects
Number of subjects: 100
Study 15346302 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with plain impingement
Number of subjects: 100
Study 15346302 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with tendinosis calcarea
Number of subjects: 100
Study 12725580 — intervention group
Group type: COMPARATOR
Intervention: Ivy leaf extract cough drops
Number of subjects: 3
Study 12725580 — intervention group
Group type: COMPARATOR
Intervention: Ivy leaf extract syrup
Number of subjects: 3
Study 12725580 — intervention group
Group type: COMPARATOR
Intervention: Ivy leaf extract suppositories
Number of subjects: 3
Study 10350027 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride 50 mg
Number of subjects: 21
Study 10350027 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride 400 mg
Number of subjects: 21
Study 10350027 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol 4 mg
Number of subjects: 21
Study 10350027 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 8736055 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine and scopolamine
Number of subjects: 53
Study 8736055 — intervention group
Group type: COMPARATOR
Intervention: Morphine alone
Number of subjects: 53
Study 1915134 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine i.v. (20 mg)
Number of subjects: 235
Study 1915134 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo i.v. and scopolamine transdermally (0.5 mg)
Number of subjects: 235
Study 1915134 — intervention group
Group type: COMPARATOR
Intervention: Saline i.v. and saline transdermally
Number of subjects: 235
Study 1915134 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermally applied scopolamine (0.5 mg)
Number of subjects: 235
Study 7041931 — intervention group
Group type: EXPERIMENTAL
Intervention: Phentolamine 0.5 mg min‐1 infusion
Number of subjects: 0
Study 7041931 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 2414066 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard formulation (buclizine 6.25 mg, codeine 8 mg, paracetamol 500 mg, with docusate sodium 10 mg)
Number of subjects: 10
Study 2414066 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination without docusate (buclizine 6.25 mg, codeine 8 mg, paracetamol 500 mg)
Number of subjects: 10
Study 2414066 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol alone (500 mg)
Number of subjects: 10
Study 31321651 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiomics signature based on T2-weighted images (T2WIs) incorporating 17 selected radiomics features
Number of subjects: 119
Study 30701912 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery (BS)
Number of subjects: 0
Study 27838646 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide (17.4 μg over a 6-hour and 15-minute infusion)
Number of subjects: 120
Study 27838646 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 120
Study 27838646 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 23594059 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy intervention at a primary health centre (PHCG)
Number of subjects: 52
Study 23594059 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy intervention at the patients' place of domicile (DG)
Number of subjects: 52
Study 22409923 — intervention group
Group type: EXPERIMENTAL
Intervention: Kanli Granule (Chinese herbs group)
Number of subjects: 80
Study 22409923 — intervention group
Group type: COMPARATOR
Intervention: Western medicine (control group)
Number of subjects: 80
Study 20820124 — intervention group
Group type: EXPERIMENTAL
Intervention: Taegyo program for 4 weeks
Number of subjects: 52
Study 17149753 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram 10 mg/day
Number of subjects: 240
Study 17149753 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine 20 mg/day
Number of subjects: 240
Study 16153925 — intervention group
Group type: EXPERIMENTAL
Intervention: MCRI On-X valve
Number of subjects: 52
Study 16153925 — intervention group
Group type: COMPARATOR
Intervention: CarboMedics Top Hat valve
Number of subjects: 52
Study 14640996 — intervention group
Group type: EXPERIMENTAL
Intervention: Cushing's syndrome patients (ET-1 levels)
Number of subjects: 13
Study 14640996 — intervention group
Group type: EXPERIMENTAL
Intervention: Adrenal adenoma patients
Number of subjects: 13
Study 14640996 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who died of severe cardiovascular complications
Number of subjects: 13
Study 14640996 — intervention group
Group type: EXPERIMENTAL
Intervention: Cushing's syndrome patients (cholesterol correlation)
Number of subjects: 13
Study 14640996 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful treatment of hypercortisolism
Number of subjects: 13
Study 11000585 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary balloon inflation during RCA angioplasty
Number of subjects: 7
Study 11000585 — intervention group
Group type: EXPERIMENTAL
Intervention: Recovery after balloon deflation
Number of subjects: 7
Study 8814846 — intervention group
Group type: EXPERIMENTAL
Intervention: Step planimetry
Number of subjects: 45
Study 8814846 — intervention group
Group type: COMPARATOR
Intervention: Dimensional method
Number of subjects: 45
Study 8814846 — intervention group
Group type: COMPARATOR
Intervention: Dimensional method with anterior deflection of the probe
Number of subjects: 45
Study 8814846 — intervention group
Group type: COMPARATOR
Intervention: Dimensional method with posterior deflection of the probe
Number of subjects: 45
Study 8814846 — intervention group
Group type: COMPARATOR
Intervention: Computer-enhanced images
Number of subjects: 45
Study 8814846 — intervention group
Group type: EXPERIMENTAL
Intervention: Dimensional method using maximum dimensions from planimetric contours
Number of subjects: 45
Study 8814846 — intervention group
Group type: COMPARATOR
Intervention: TRUS using the prolate ellipsoid formula
Number of subjects: 45
Study 1505304 — intervention group
Group type: EXPERIMENTAL
Intervention: HUL/R (twice-daily humulin ultralente insulin)
Number of subjects: 31
Study 1505304 — intervention group
Group type: COMPARATOR
Intervention: HL/R (control group)
Number of subjects: 31
Study 1505304 — intervention group
Group type: EXPERIMENTAL
Intervention: HUL/R and HL/R
Number of subjects: 31
Study 6388585 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of clotrimazole and hydrocortisone (Canesten HC)
Number of subjects: 192
Study 6388585 — intervention group
Group type: COMPARATOR
Intervention: Clotrimazole alone
Number of subjects: 192
Study 6388585 — intervention group
Group type: COMPARATOR
Intervention: Hydrocortisone alone
Number of subjects: 192
Study 6388585 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of clotrimazole and hydrocortisone
Number of subjects: 192
Study 30771607 — intervention group
Group type: EXPERIMENTAL
Intervention: Childbirth preparation course
Number of subjects: 133
Study 30771607 — intervention group
Group type: COMPARATOR
Intervention: Standard care in antenatal clinics
Number of subjects: 133
Study 29391277 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi
Number of subjects: 171
Study 29391277 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Number of subjects: 171
Study 29391277 — intervention group
Group type: COMPARATOR
Intervention: Tai Chi and Physical Therapy
Number of subjects: 171
Study 27828820 — intervention group
Group type: EXPERIMENTAL
Intervention: Large-pore lightweight composite mesh placed in the intraperitoneal/onlay fashion using a modified Sugarbaker technique
Number of subjects: 52
Study 27828820 — intervention group
Group type: COMPARATOR
Intervention: Nonmesh (control group)
Number of subjects: 52
Study 27828820 — intervention group
Group type: EXPERIMENTAL
Intervention: Large-pore lightweight composite mesh
Number of subjects: 52
Study 25270008 — intervention group
Group type: EXPERIMENTAL
Intervention: Earplugs with NRR of 25 with training
Number of subjects: 150
Study 25270008 — intervention group
Group type: COMPARATOR
Intervention: Earplugs with NRR of 25 without training
Number of subjects: 150
Study 25270008 — intervention group
Group type: COMPARATOR
Intervention: Earplugs with NRR of 30 without training
Number of subjects: 150
Study 22436121 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex care continuum intervention involving collaboration between a nurse with geriatric expertise, hospital ward staff, and a multi-professional team with a case manager
Number of subjects: 18
Study 22436121 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation fidelity evaluation
Number of subjects: 18
Study 20515284 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarker testing (e.g., troponin)
Number of subjects: 0
Study 20515284 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic intervention (e.g., cardiac catheterization)
Number of subjects: 0
Study 20515284 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation modelling studies
Number of subjects: 0
Study 18068058 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapleural analgesia with 20 mL of 0.5% bupivacaine every 6 hours for 4 days
Number of subjects: 125
Study 15545509 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen
Number of subjects: 309
Study 15545509 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen plus progestin
Number of subjects: 309
Study 15545509 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 309
Study 15545509 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 309
Study 12011120 — intervention group
Group type: EXPERIMENTAL
Intervention: Azacitidine (Aza C) 75 mg/m(2)/d subcutaneously for 7 days every 28 days
Number of subjects: 191
Study 12011120 — intervention group
Group type: COMPARATOR
Intervention: Supportive care
Number of subjects: 191
Study 12011120 — intervention group
Group type: EXPERIMENTAL
Intervention: Azacitidine (Aza C)
Number of subjects: 191
Study 9803110 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorzolamide (one drop immediately after surgery)
Number of subjects: 59
Study 9803110 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide (250 mg SR orally immediately post-operatively)
Number of subjects: 59
Study 9803110 — intervention group
Group type: COMPARATOR
Intervention: Control (received neither intervention)
Number of subjects: 59
Study 7814228 — intervention group
Group type: EXPERIMENTAL
Intervention: Counterrotational electric toothbrush
Number of subjects: 12
Study 7814228 — intervention group
Group type: COMPARATOR
Intervention: Manual toothbrush
Number of subjects: 12
Study 7814228 — intervention group
Group type: EXPERIMENTAL
Intervention: Both brushes (Counterrotational electric toothbrush and Manual toothbrush)
Number of subjects: 12
Study 2916783 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% N2O/70% O2
Number of subjects: 34
Study 2916783 — intervention group
Group type: COMPARATOR
Intervention: 100% O2
Number of subjects: 34
Study 791332 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxprenolol alone
Number of subjects: 0
Study 791332 — intervention group
Group type: COMPARATOR
Intervention: Phentolamine (sustained administration)
Number of subjects: 0
Study 791332 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of oxprenolol and phentolamine
Number of subjects: 0
Study 791332 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol (400 mg daily)
Number of subjects: 0
Study 31110380 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic device
Number of subjects: 38
Study 31110380 — intervention group
Group type: COMPARATOR
Intervention: Bipolar diathermy
Number of subjects: 38
Study 28921414 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia diabetes education program and nutrition therapy (NT + MDE)
Number of subjects: 351
Study 28921414 — intervention group
Group type: COMPARATOR
Intervention: Nutrition therapy only (NT)
Number of subjects: 351
Study 25695189 — intervention group
Group type: COMPARATOR
Intervention: Ropivacaine alone (R)
Number of subjects: 24
Study 25695189 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine with 50 μg dexmedetomidine (RD50)
Number of subjects: 24
Study 25695189 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine with 100 μg dexmedetomidine (RD100)
Number of subjects: 24
Study 25695189 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine with 150 μg dexmedetomidine (RD150)
Number of subjects: 24
Study 25695189 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine with dexmedetomidine (all doses)
Number of subjects: 24
Study 24021222 — intervention group
Group type: EXPERIMENTAL
Intervention: Distraction
Number of subjects: 70
Study 24021222 — intervention group
Group type: EXPERIMENTAL
Intervention: Reappraisal
Number of subjects: 70
Study 24021222 — intervention group
Group type: COMPARATOR
Intervention: No-instruction control condition
Number of subjects: 70
Study 21947289 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure target <140/90 mm Hg
Number of subjects: 0
Study 21947289 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure target <130/80 mm Hg
Number of subjects: 0
Study 21947289 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased frequency of BP control to <140/90 mm Hg
Number of subjects: 0
Study 21947289 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased frequency of BP control to <130/80 mm Hg
Number of subjects: 0
Study 18321486 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (500 mg three times a day)
Number of subjects: 115
Study 18321486 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (incremental dose)
Number of subjects: 115
Study 18321486 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of metformin and clomiphene citrate
Number of subjects: 115
Study 17204136 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitor (SSRI) plus general practitioner (GP) supportive care
Number of subjects: 300
Study 17204136 — intervention group
Group type: COMPARATOR
Intervention: Supportive care alone
Number of subjects: 300
Study 15515443 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoor gardening activities, once a week for 5 weeks
Number of subjects: 66
Study 15515443 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-week intervention program
Number of subjects: 66
Study 15515443 — intervention group
Group type: COMPARATOR
Intervention: Control group received a 20-minute visit
Number of subjects: 66
Study 11587494 — intervention group
Group type: COMPARATOR
Intervention: Naratriptan 0 mg
Number of subjects: 150
Study 11587494 — intervention group
Group type: EXPERIMENTAL
Intervention: Naratriptan 2.5 mg
Number of subjects: 150
Study 11587494 — intervention group
Group type: EXPERIMENTAL
Intervention: Naratriptan 5 mg
Number of subjects: 150
Study 11587494 — intervention group
Group type: EXPERIMENTAL
Intervention: Naratriptan 10 mg
Number of subjects: 150
Study 11587494 — intervention group
Group type: EXPERIMENTAL
Intervention: Naratriptan 20 mg
Number of subjects: 150
Study 11587494 — intervention group
Group type: COMPARATOR
Intervention: Sub-D-optimal design with Naratriptan 0 mg
Number of subjects: 150
Study 11587494 — intervention group
Group type: EXPERIMENTAL
Intervention: Sub-D-optimal design with Naratriptan 10 mg
Number of subjects: 150
Study 9154396 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamisil DermGel (terbinafine 1% emulsion gel) applied once daily for 7 days
Number of subjects: 61
Study 9154396 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel applied once daily for 7 days
Number of subjects: 61
Study 7957547 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumequine (400 mg, three times daily for 5 days)
Number of subjects: 8
Study 7957547 — intervention group
Group type: COMPARATOR
Intervention: Theophylline (single i.v. dose)
Number of subjects: 8
Study 3819220 — intervention group
Group type: EXPERIMENTAL
Intervention: Grass-pollen immunotherapy (IT)
Number of subjects: 18
Study 3819220 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 18
Study 29652278 — intervention group
Group type: EXPERIMENTAL
Intervention: Glargine + human insulin infusion during perioperative period
Number of subjects: 50
Study 29652278 — intervention group
Group type: COMPARATOR
Intervention: Normal saline + human insulin infusion during perioperative period
Number of subjects: 50
Study 27436224 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter Ablation
Number of subjects: 52
Study 27436224 — intervention group
Group type: COMPARATOR
Intervention: Rate Control
Number of subjects: 52
Study 24510656 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg/day
Number of subjects: 2446
Study 24510656 — intervention group
Group type: COMPARATOR
Intervention: Comparator (active comparator or placebo)
Number of subjects: 2446
Study 22325089 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy for 8 months
Number of subjects: 119